Sanofi strengthens vaccines manufacturing capacity in Singapore
The company will invest €400 million in a new site to enable it to produce vaccines on a massive scale for Asia
Building on last month's announcement of its plan to construct a new facility in Canada to increase its global availability of high-dose flu vaccines, Sanofi has now said it is also investing €400 million to create a unique vaccine production centre in Singapore.
The five-year project is currently entering its design phase with construction expected to begin in Q3 2021, with the site expected to be fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed.
Sanofi said the facility will "push the boundaries of operation through cutting-edge manufacturing and digital technologies."
"By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur.
The factory will be designed around a central unit housing several fully digitalized modules allowing production of three to four vaccines simultaneously, versus only one in current industrial sites.
It will also be able to leverage multiple vaccine manufacturing technology platforms based on different cell types, allowing the production of a specific vaccine to be prioritized in a faster timeframe depending on public health needs, Sanofi said.
Dr Beh Swan Gin, Chairman of the Singapore Economic Development Board said Sanofi’s decision to locate its first-in-Asia digitally-enabled vaccine production center in Singapore "is an endorsement of Singapore’s position as a leading centre for advanced manufacturing."
The project is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry.
Last month, Sanofi announced it would invest more than €600 million to build a vaccine manufacturing facility at its existing site in Toronto to provide additional antigen and filling capacity for its Fluzone influenza vaccine for the Canadian, US and European markets.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance